Evidence map›Paper›PMID 33472921›Full record

ArticleNeurology2021

Prevalence of Imaging Targets in Patients With Minor Stroke Selected for IV tPA Treatment Using MRI: The Treatment of Minor Stroke With MRI Evaluation Study (TIMES).

Amie W Hsia, Marie L Luby, Richard Leigh, John K Lynch, Zurab Nadareishvili, Richard T Benson, Chandni Kalaria, Shannon P Burton, Larry Latour

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Amie W HsiaFrom the Stroke Branch (A.W.H., M.L.L., R.L., J.K.L., Z.N., R.T.B., C.K., S.P.B., L.L.), NIH/National Institute of Neurological Disorders and Stroke, Bethesda, MD; MedStar Washington Hospital Center (A.W.H., R.T.B., C.K., S.P.B.), Washington, DC; and Suburban Hospital (Z.N.), Johns Hopkins Medicine, Bethesda, MD. hsiaa@ninds.nih.gov.
Marie L LubyFrom the Stroke Branch (A.W.H., M.L.L., R.L., J.K.L., Z.N., R.T.B., C.K., S.P.B., L.L.), NIH/National Institute of Neurological Disorders and Stroke, Bethesda, MD; MedStar Washington Hospital Center (A.W.H., R.T.B., C.K., S.P.B.), Washington, DC; and Suburban Hospital (Z.N.), Johns Hopkins Medicine, Bethesda, MD.
Richard LeighFrom the Stroke Branch (A.W.H., M.L.L., R.L., J.K.L., Z.N., R.T.B., C.K., S.P.B., L.L.), NIH/National Institute of Neurological Disorders and Stroke, Bethesda, MD; MedStar Washington Hospital Center (A.W.H., R.T.B., C.K., S.P.B.), Washington, DC; and Suburban Hospital (Z.N.), Johns Hopkins Medicine, Bethesda, MD.
John K LynchFrom the Stroke Branch (A.W.H., M.L.L., R.L., J.K.L., Z.N., R.T.B., C.K., S.P.B., L.L.), NIH/National Institute of Neurological Disorders and Stroke, Bethesda, MD; MedStar Washington Hospital Center (A.W.H., R.T.B., C.K., S.P.B.), Washington, DC; and Suburban Hospital (Z.N.), Johns Hopkins Medicine, Bethesda, MD.
Zurab NadareishviliFrom the Stroke Branch (A.W.H., M.L.L., R.L., J.K.L., Z.N., R.T.B., C.K., S.P.B., L.L.), NIH/National Institute of Neurological Disorders and Stroke, Bethesda, MD; MedStar Washington Hospital Center (A.W.H., R.T.B., C.K., S.P.B.), Washington, DC; and Suburban Hospital (Z.N.), Johns Hopkins Medicine, Bethesda, MD.
Richard T BensonFrom the Stroke Branch (A.W.H., M.L.L., R.L., J.K.L., Z.N., R.T.B., C.K., S.P.B., L.L.), NIH/National Institute of Neurological Disorders and Stroke, Bethesda, MD; MedStar Washington Hospital Center (A.W.H., R.T.B., C.K., S.P.B.), Washington, DC; and Suburban Hospital (Z.N.), Johns Hopkins Medicine, Bethesda, MD.
Chandni KalariaFrom the Stroke Branch (A.W.H., M.L.L., R.L., J.K.L., Z.N., R.T.B., C.K., S.P.B., L.L.), NIH/National Institute of Neurological Disorders and Stroke, Bethesda, MD; MedStar Washington Hospital Center (A.W.H., R.T.B., C.K., S.P.B.), Washington, DC; and Suburban Hospital (Z.N.), Johns Hopkins Medicine, Bethesda, MD.
Shannon P BurtonFrom the Stroke Branch (A.W.H., M.L.L., R.L., J.K.L., Z.N., R.T.B., C.K., S.P.B., L.L.), NIH/National Institute of Neurological Disorders and Stroke, Bethesda, MD; MedStar Washington Hospital Center (A.W.H., R.T.B., C.K., S.P.B.), Washington, DC; and Suburban Hospital (Z.N.), Johns Hopkins Medicine, Bethesda, MD.
Larry LatourFrom the Stroke Branch (A.W.H., M.L.L., R.L., J.K.L., Z.N., R.T.B., C.K., S.P.B., L.L.), NIH/National Institute of Neurological Disorders and Stroke, Bethesda, MD; MedStar Washington Hospital Center (A.W.H., R.T.B., C.K., S.P.B.), Washington, DC; and Suburban Hospital (Z.N.), Johns Hopkins Medicine, Bethesda, MD.
MedStar Washington Hospital Center · US

Funding

CLINICAL AND IMAGING CORE SUPPORT OF ACUTE STROKE RESEARCHZICNS003044 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI LATOUR, LAWRENCE · 2015 to 2025
$32.8M
NOVEL INSIGHTS INTO CEREBRAL ISCHEMIC PATHOPHYSIOLOGY IN HUMANSZIANS003043 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI LATOUR, LAWRENCE · 2009 to 2025
$19.5M
6 · The paper itself

Abstract

objectiveTo determine the IV tissue plasminogen activator (tPA) treatment rate of patients with minor acute ischemic stroke (mAIS) at our centers and compare the frequency of MRI targets by treatment stratification and clinical severity, we evaluated clinical characteristics and baseline MRIs for tPA-treated and untreated patients.

methodsPatients with ischemic stroke from 2015 to 2017 with admit NIH Stroke Scale (NIHSS) <6 were considered. The treated cohort received standard IV tPA and was screened with baseline MRI. The untreated cohort received no acute intervention and baseline MRI was <4 hours from onset. Patients were stratified into "clearly" and "not clearly" disabling deficits by NIHSS elements. Baseline MRI was evaluated by independent raters for AIS targets, with frequencies compared between groups.

resultsOf 255 patients with mAIS ≤4.5 hours from onset, 140 (55%) received IV tPA, accounting for 46% of all IV tPA patients (n = 305). Eighty-five percent (n = 119) were screened with baseline MRI and had significantly more frequent imaging targets compared to those untreated (n = 90). Of this treated cohort, 75% (n = 89) were not clearly disabling. Except for perfusion-diffusion mismatch (81% clearly disabling vs 56% not clearly disabling [

conclusionsIn MRI-screened mAIS, imaging targets were more frequently seen in patients treated with IV tPA, with similar frequencies even in those without clearly disabling deficits. MRI targets could be used to guide thrombolytic therapy in patients with mAIS; however, a randomized trial is needed to demonstrate efficacy.

Indexed as

AgedAged, 80 and overCohort StudiesDisability EvaluationFemaleHumansImage Processing, Computer-AssistedInjections, IntravenousIschemic StrokeMagnetic Resonance ImagingMaleMiddle AgedPlasminogen ActivatorsRecovery of FunctionTime-to-TreatmentTissue Plasminogen ActivatorPlasminogen ActivatorsTissue Plasminogen Activator

Identifiers

PMID33472921
PMCPMC8055325
OpenAlexW3123464456

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.